Alfred Sandrock Sells 12,192 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 12,192 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $3.78, for a total value of $46,085.76. Following the completion of the sale, the chief executive officer owned 509,989 shares of the company’s stock, valued at $1,927,758.42. This represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Voyager Therapeutics Trading Down 6.3%

VYGR opened at $3.42 on Friday. The company has a market capitalization of $190.15 million, a price-to-earnings ratio of -1.58 and a beta of 1.30. Voyager Therapeutics, Inc. has a 12-month low of $2.64 and a 12-month high of $5.55. The business’s fifty day simple moving average is $4.00 and its 200-day simple moving average is $4.08.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.06. The company had revenue of $11.15 million during the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. On average, equities research analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on VYGR. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright reduced their target price on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently made changes to their positions in the business. Bank of Montreal Can purchased a new position in Voyager Therapeutics during the 2nd quarter worth $36,000. Wexford Capital LP purchased a new stake in shares of Voyager Therapeutics during the third quarter worth about $42,000. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics during the fourth quarter valued at about $44,000. CIBC Asset Management Inc purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at approximately $45,000. Finally, R Squared Ltd acquired a new stake in Voyager Therapeutics in the 2nd quarter worth approximately $48,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.